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Abstract
 . 2qIn catfish Ictalurus punctatus hepatocytes angiotensin II induced an immediate increase in cytosolic Ca concentra-
tion. Other angiotensin analogues also induced this effect including: human angiotensin II, fish angiotensin II, human
angiotensin III, human angiotensin I, fish angiotensin I and saralasin. CGP 42112A induced a very small effect at the
highest concentration tested and angiotensin IV was without effect. Angiotensin II also increased the resynthesis of
phosphatidylinositol and the production of IP . These physiological effects were not blocked by losartan AT -selective3 1
.  .antagonist or PD 123177 AT -selective antagonist .2
w125 x  .I Angiotensin II bound to liver plasma membranes in a saturable fashion with high affinity K 2.7 nM and a BD max
of 185 fmolrmg of protein. Binding competition experiments showed the following order of potency: human angiotensin
IIs fish angiotensin II)human angiotensin IIIGhuman angiotensin Is fish angiotensin I. These sites were insensitive to
losartan or PD 123177.
The data indicate that the angiotensin II receptors expressed in catfish hepatocytes are coupled to the phosphoinositide
turnoverrcalcium mobilization signal transduction pathway and are atypical receptors, i.e., pharmacologically distinct from
mammalian AT and AT receptors.1 2
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1. Introduction
 .Angiotensin II AII is a multifunctional octapep-
tide hormone that regulates a plethora of physio-
logical actions by interacting with cells surface recep-
w xtors 1,2 . In mammalian tissues, at least two types of
 .angiotensin II receptors AT and AT have been1 2
identified by pharmacological and molecular biologi-
w xcal approaches 2–5 . Both receptors belong to the
seven-transmembrane domains superfamily of G pro-
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tein-coupled receptors and differ in their affinities
and selectivity for synthetic non-peptide antagonists
w x3–5 . Thus, AT receptors have high affinity for1
losartan and very low affinity for PD123177 whereas
AT receptors display the opposite order of affinities2
w xfor these nonpeptide antagonists 3–5
AT receptors mediate most of the best known1
actions of AII and are coupled to the phosphoinosi-
tide turnoverr calcium mobilization signal transduc-
w xtion process 2,6,7 . Depending on the cell type, these
receptors can also be coupled to other effector sys-
tems such as phospholipases A and D, as well as2
voltage dependent Ca2q channels, and to inhibition
w xof adenylyl cyclase 7,8 . The signal transduction
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mechanism utilized by AT receptors is not yet com-2
pletely understood. However, it has been proposed
these receptors regulate the activity of tyrosine phos-
w xphatases 9,10 .
There is a third group of heterogeneous an-
giotensin receptors that share one common character-
istic: that is, they have little affinity for either AT or1
AT receptor nonpeptide antagonist. This group of2
w xreceptors, named atypical receptors 5 , have been
described in some tissues of non-mammalian verte-
w xbrates, including amphibians 11–14 and birds
w x15,16 . Other atypical receptors, such as those ob-
served in differentiated mouse neuroblastoma cells
w x w x17 , aortic canine tissue 18 , and in an epithelial cell
w xline derived from the rat small intestine 19 , have in
common a much reduced affinity for the nonpeptide
antagonists.
In rat liver cells, AII activates phosphorylase a
activity via the phosphoinositide turnoverrcalcium
mobilization signal transduction pathway through AT1
w xreceptors 6,7 ; these receptors are also coupled, in an
w xinhibitory fashion, to adenylyl cyclase 7 . During our
studies on the a -adrenoceptors expressed in the liver1
w xof different species 20,21 , we observed that AII
increases intracellular calcium in catfish hepatocytes.
Previous studies have shown the existence of AII
w xreceptors in teleost liver cells 22–25 . Janssens et al.
w x22 showed that AII decreases glucose release in
carp liver, although the signal transduction and the
 .  .type s of receptor s involved were not defined.
w xCobb and Brown 23 detected AII binding to rain-
bow trout tissues by autoradiography. Marsigliante
w xand co-workers 24,25 , identified two AII receptors
 .expressed by the eel Anguilla anguilla ; one of
them, was recognized by a monoclonal antibody
w xraised against mammalian AT receptors 24,25 . We1 (characterized the AII receptors of catfish Ictalurus
)punctatus liver cells; our data indicate that these
teleost liver cells express atypical receptors which are
coupled to the phosphoinositide turnoverrcalcium
mobilization signal transduction process.
2. Materials and methods
Human angiotensin I, human AII, human an-
w 1 5x .giotensin III, fish AII Asn , Val AII , goosefish
w 1 5x .angiotensin I Asn , Val agiotensin I , saralasin
w 1 8x . Sar , Ala AII , HEPES N-2-hydroxyethylpipera-
X .zine-N -2-ethanesulfonic acid and bacitracin were
obtained from Sigma Chemical Co. Indo-1rAM was
from Molecular Probes, CGP 42112A from Research
Biochemicals International and bovine serum albu-
 .min fraction V from Armour. Inositol-1,4,5-tri-
w125sphosphate radioreceptor assay kits, human I-
4 x  . w32 x  .Tyr AII 2200 Cirmmol and P Pi carrier free
were from New England Nuclear. Losartan DUP
.753 and PD 123177 were generously provided by
The DuPont Merck Pharmaceutical Company.
Adult catfish, Ictalurus punctatus, weighing 200–
300 g were purchased from a local dealer and main-
tained in Centro Acuıcola ‘La Paz’ water tempera-´
.ture 25"58C . Animals were transported to the labo-
ratory 4–5 days before experimentation; animals were
placed in tanks containing 150 l of dechlorinated tap
 .water at room temperature 23–258C that was con-
tinuously aerated.
Hepatocytes were isolated by liver retrograde per-
w xfusion with collagenase 26 and were incubated in
the following buffer: 136 mM NaCl, 5.4 mM KCl,
0.81 mM MgSO , 5 mM NaHCO , 0.33 mM4 3
Na HPO , 10 mM HEPES, pH was adjusted to 7.632 4
w x w x27 . All incubations were performed at 208C 21 .
w 2qx .Intracellular calcium Ca and IP determina-I 3
w 2qx w xtions: Ca was determined as described 21 . InI
brief, hepatic cells were loaded with 10 mM indo-
1rAM for 30 min at room temperature and washed
with the same buffer mentioned above. Excitation
and emission wavelengths of 340 and 410 nm were
employed. The fluorimeter AMINCO-Bowman Se-
.ries 2 Luminescence Spectrometer was fitted with a
magnetic stirrer.
Production of IP was carried out according to3
w xFabbri et al. 28 with minor modifications. In brief,
cell suspensions 1 ml containing 50 mg of cells wet
.weight were incubated at 208C in presence of AII or
other agonists; antagonists were added 5 min before
the agonist. Reactions were stopped at 30 s or the
indicated times by adding ice-cold perchloric acid
 .6% final concentration . Acidified samples were vor-
texed and kept on ice for 1 h before centrifugation at
2000=g for 15 min. Supernatants were removed
and neutralized with 1.5 M KOHr75 mM Hepes;
100 ml of these neutralized supernatants were used
for quantification, employing a commercial IP ra-3
dioreceptor assay kit.
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 .Phosphatidylinositol PI labeling: PI labeling was
performed by incubating the cells for 60 min in
buffer without sodium phosphate and supplemented
w32 xwith 10 mCirml of P Pi. At the end of the incuba-
tion lipids were extracted with chloroformrmethanol
 .2:1 and phospholipids separated by one-dimen-
w xsional thin-layer chromatography 29 .
w125 xMembrane preparation and I AII binding as-
says: Liver membranes were isolated by the discon-
tinuous sucrose density gradient method of Neville
w x w125 x30 . Human I AII binding was performed as de-
w x scribed 31 . In brief, catfish liver membranes 50 mg
.protein were incubated in a total volume of 100 ml
of buffer containing: 100 mM NaCl, 10 mM MgCl ,2
0.2% bovine serum albumin, 0.1 mgrml bacitracin,
20 mM Tris, pH 7.5. Incubations were in a water
bath shaker at 128C, after 60 min 3 ml of ice-cold
buffer were added to the membrane suspension; the
membranes were immediately filtered on GFrC fil-
 .ters and washed three times 3 ml each time with the
same buffer. Filters were presoaked in 0.3% polyeth-
ylenimine to decrease nonspecific binding to the fil-
ter. Saturation experiments were performed using
w125 xconcentrations in the range of 0.5–150 nM I AII
and binding competition studies with 0.3–0.5 nM
 .radioactive ligand 15–20% receptor occupation .
Nonspecific binding was evaluated in the presence of
1 mM AII; specific binding represented 90–95% of
the total binding at the K . Binding saturation andD
competition data were analyzed using the RADLIG
 .program Biosoft-Elsevier . K values were calcu-i
w xlated according to Cheng and Prussoff 32 .
3. Results
In catfish hepatocytes 1 mM human AII induced
w 2qxan almost immediate increase in Ca that returnedI
 .very slowly to near basal levels Fig. 1 . AII also
w 2qxincreased Ca in cells incubated in buffer withoutI
calcium and containing 25 mM EGTA data not
.shown . At lower concentrations of human an-
 . w 2qxgiotensin II 1 pM to 1 nM Ca increased in anI
oscillatory pattern, as described for a -adrenergic1
w xagents 21 . The effects of human AII, and those of
the different analogues tested, were dose-dependent
 .Fig. 2 . It can be observed that fish AII was as
potent and as effective as human AII to increase
w 2q xFig. 1. Effect of angiotensin II on Ca . Cells were equili-I
brated in the fluorimeter and 1 mM angiotensin II was added. A
representative experiment, of nine performed with different cell
preparations, is presented.
w 2qxCa and reached a maximum of 2.5- to 3-foldi
over basal, the EC values for both of these agents50
were f1 nM. Human angiotensin III was also as
Fig. 2. Effect of angiotensin II and angiotensin analogues on
w 2q xCa . Cells were incubated in the presence of different con-I
 .centrations of human angiotensin II filled circles , fish an-
 .  .giotensin II filled squares , human angiotensin III open squares ,
 .  .saralasin filled diamonds , human angiotensin I filled triangles ,
 .  .fish angiotensin I open triangles , CGP 42112A open circles ,
 .or angiotensin IV open diamonds . Results are expressed as
w 2q xpercentage of basal Ca , which was 111"5 nM. Plotted areI
the means and vertical lines represent the S.E.M. of 6–8 experi-
ments performed with different cell preparations.
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effective as the two AII analogues but it was slightly,
 .but consistently, less potent EC f3 nM . Sar-50
alasin, an AII analogue, that in some systems behaves
as an antagonistr partial agonist, clearly induced an
w 2qxalmost full Ca response at the highest concentra-I
 .tion tested 1 mM ; similar effects were observed
with the human and fish forms of angiotensin I Fig.
.2 . CGP 42112A, a peptide analogue of AII, behaved
as a weak agonist, inducing a very small effect at the
 .  .highest concentration tested 1 mM Fig. 2 . Recent
studies have shown novel binding sites for the C-
terminal 3–8 hexapeptide fragment of AII, named
w xangiotensin IV binding sites 33 . We studied the
effect of this fragment but angiotensin IV did not
w 2qxinduce any measurable effect on Ca in isolatedI
 .fish hepatocytes at the concentrations tested Fig. 2 .
In order to determine the type of AII receptor
involved in this effect we studied the effect of the
 .non-peptide antagonists losartan AT -selective and1
 .PD123177 AT -selective . None of these agents af-2
w 2qx  .fected basal Ca by themselves data not shown .I
As shown in Fig. 3 the effects of 1mM fish AII or 1
w 2qxmM human AII on Ca were not blocked byI
 .  . either losartan 10 mM or PD 123177 10 mM Fig.
.3 . In fact neither of these nonpeptide antagonists
were able to shift the dose-response curves for these
 .AII forms data not shown .
In order to get further insights, phosphoinositide
Fig. 3. Effects of angiotensin II and angiotensin II antagonist on
w 2q x  .Ca . Cells were incubated in the absence Basal or presenceI
 .of 1 mM fish angiotensin II fAII , or 1 mM human angiotensin
 .  .II hAII alone, or with 10 mM DUP qDUP or 10 mM
 .PD123177 qPD . Results are expressed as percentage of basal
w 2q xCa , which was 90"9 nM. Plotted are the means andI
vertical lines represent the S.E.M. of 6–8 experiments performed
with different cell preparations.
Fig. 4. Effect of angiotensin II and angiotensin II antagonist on
 .phosphatidylinositol PI labeling. Cells were incubated in the
 .  .absence Basal or presence of 1 mM fish angiotensin II fAII ,
 .or 1 mM human angiotensin II hAII alone, or with 10 mM DUP
 .  .qDUP or 10 mM PD123177 qPD . Results are expressed as
percentage of basal labeling which was 153"6 cpmr100 mg
cells wet weight. Plotted are the means and vertical lines repre-
sent the S.E.M. of 5 experiments performed with different cell
preparations.
 .turnover was studied. PI labeling resynthesis is an
event secondary to phosphatidylinositol 4,5-bisphos-
phate hydrolysis. It can be observed in Fig. 4 that
both 1 mM human AII and 1 mM fish AII increased
PI labeling f4.5-fold and that these effects were not
blocked by losartan or PD123177, confirming the
previous results. No effect of the AII forms, on the
labeling of other phospholipids, was observed data
.not shown . The antagonists themselves did not alter
 .the basal labeling of PI data nor shown .
Fig. 5. Time-course of the effect of angiotensin II on inositol-
 .1,4,5-trisphosphate IP production. Cells were incubated for the3
time indicated with 1 mM angiotensin II. Plotted are the means
and vertical lines represent the S.E.M. of 4 experiments per-
formed with different cell preparations.
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Fig. 6. Effect of angiotensin II on inositol-1,4,5-trisphosphate
 .IP production. Cells were incubated in the presence of differ-3
ent concentrations of angiotensin II. Plotted are the means and
vertical lines represent the S.E.M. of 4 experiments performed
with different cell preparations
The effects of human AII on IP production was3
 .quantified in liver cells. AII 1 mM induced an
almost immediate increase in IP production 2.5–3-3
.fold over basal level that reached its maximum 30
seconds after its addition to the cells; this effect also
decreased rather rapidly reaching near basal levels,
Fig. 7. Effect of angiotensin II and angiotensin analogues on
 .inositol-1,4,5-trisphosphate IP production. Cells were incu-3
 .bated in the absence Basal or presence of 1 mM fish an-
 .  .giotensin I fAI , 1 mM fish angiotensin II fAII , 1 mM human
 .  .angiotensin I hAI , 1 mM human angiotensin II hAII , or 1 mM
 .human angiotensin III hAIII . Plotted are the means and vertical
lines represent the S.E.M. of 4 experiments performed with
different cell preparations.
Fig. 8. Effect of angiotensin II and angiotensin II antagonist on
 .inositol-1,4,5-trisphosphate IP production. Cells were incu-3
 .bated in the absence Basal or presence of 1 mM fish an-
 .  .giotensin II fAII , or 1 mM human angiotensin II hAII alone,
 .  .or with 10 mM DUP qDUP or 10 mM PD123177 qPD .
Plotted are the means and vertical lines represent the S.E.M. of 4
experiments performed with different cell preparations.
approximately 2–5 min after hormone addition Fig.
.5 . The effect of human AII was dose-dependent with
 .an EC of f40 nM Fig. 6 .50
The effect of AII analogues on IP production was3
evaluated and the data shown in Fig. 7. The agents
were tested at a concentration of 1 mM and the
magnitude of the effect observed was: fish AIIG
human AII s human angiotensin III ) fish an-
giotensin IGhuman angiotensin I. The effects of
human or fish AII on IP production were not blocked3
by the angiotensin II antagonists, losartan and
 .PD123177 Fig. 8 . The antagonists by themselves
w125 xFig. 9. I Angiotensin II saturation isotherm using fish liver
membranes. Plotted is the specific binding and the Rosenthal
 .analysis insert . The figure is representative of five experiments
using different membrane preparations.
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Fig. 10. Binding competition experiments using fish liver mem-
branes. The following agonist were employed: human angiotensin
 .  .II filled circles , fish angiotensin II filled squares , human
 . angiotensin III open squares , human angiotensin I filled trian-
.  . gles , fish angiotensin I open triangles , DUP753 filled dia-
.  .monds , and PD123177 open diamonds . The figure is represen-
tative of 3–6 experiments using different membrane preparations.
were without effect on this parameter data not
.shown .
w125 xRadioligand binding studies using human I AII
were performed to further assess the pharmacological
properties of the AII receptor present in catfish hepa-
w125 xtocytes. Human I AII bound to liver plasma mem-
branes in a saturable fashion with high affinity K D
.2.7"0.5 nM and a B of 185"41 fmolrmg ofmax
protein was detected results are the means"S.E.M.
of 4 determinations using different membrane prepa-
rations; a representative saturation isotherm is pre-
.sented in Fig. 9 . Binding competition experiments
 .Fig. 10 indicated the following order of potency:
human AIIs fish AII)human angiotensin IIIs
 .human angiotensin Is fish angiotensin I Table 1 . In
Table 1
w125 xParameters derived from the I angiotensin II binding competi-
tion curves
 .Agent K nM Slopei
 .Human angiotensin II 4 3.6"0.4 0.83"0.18
 .Fish angiotensin II 4 5.7"1.3 0.96"0.20
 .Human angiotensin III 3 62.0"13.0 0.87"0.03
 .Human angiotensin I 6 79.0"24.0 1.09"0.13
 .Fish angiotensin I 4 97.0"14.0 0.73"0.10
 .Losartan 4 -10 000 –
 .PD123177 4 -10 000 –
Results are the mean"S.E.M. with the number of determinations
using different membrane preparations in parentheses.
contrast, the non-peptide antagonist, losartan or
w125 xPD123177, did not compete for the I AII binding
sites present in catfish liver membranes Fig. 10 and
.Table 1 .
4. Discussion
The present data indicate that AII receptors are
expressed in catfish hepatic cells and modulate cal-
cium mobilization. This response is observed in cells
incubated in buffer without Ca2q and containing
w 2qxEGTA which indicated that such increases in Ca I
are due to the release of this cation from intracellular
stores. Therefore, we determined phosphoinositide
turnover. Our data clearly indicate that AII induced
the production of the second messenger IP and a3
secondary resynthesis of PI. These data indicate that
the AII receptors present in catfish hepatocytes acti-
vate the phosphoinositide turnoverr calcium mobi-
lization signal transduction process as it has been
w xobserved for AT receptors 2,5–8 .1
 .The AII EC for IP production f40 nM is50 3
w 2qx bigger than that observed in the Ca studies f1I
.nM which suggests that the former is not subject to
amplification and that, therefore, this effect is more
closely related to receptor activation. It is clear that
w 2qx10 nM AII induced a near maximal Ca responseI
whereas this concentration of the peptide stimulated
IP production only to a relatively small extent.3
These data indicate that, although the density of AII
sites detected is not very big, there is some receptor
w 2qxreserve for the Ca response.I
The actions elicited by activation of the AII recep-
tor present in fish hepatocytes are insensitive to the
well known nonpeptide AII receptor antagonists
losartan and PD 123177. Furthermore, the binding
competition experiments showed that such receptors
have negligible affinity for these AII nonpeptide an-
tagonists. These data suggest that the AII receptors
expressed in fish hepatocytes should be considered
among the atypical receptors such as those observed
w x w xin amphibians 11–14 and birds 15,16 .
AII is an octapeptide whose sequence, Asp-Arg-
Val-Tyr-Ile-His-Pro-Phe, is present in human and
most mammals. This sequence has been conserved
during evolution and the amino acid sequences deter-
mined to date indicate great similarity among verte-
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brates angiotensin II isoforms. In teleost fish only
two changes have been observed: Asp1 “Asn and
5 w xIle “Val 34 . These changes in sequence, between
fish and human angiotensins, do not seem to be
critical for their biological activity in catfish hepato-
cytes since no major differences in the functional
responses or in binding affinity were observed. This
is consistent with structure-activity studies which have
indicated that the carboxyl-terminus of the molecule
and the three aromatic side groups Try, His and
. w xPhe , play the major role in determining activity 35 .
Like the mammalian AII receptors, the catfish
receptor bound AII analogues with nanomolar affin-
ity. However, binding competition assay demon-
strated some differences with the cloned mammalian
receptors where it has been observed that AII is
slightly more potent than angiotensin III at AT1
 . w xreceptors f4-fold 16 , AII and angiotensin III are
w xequipotent at AT receptors 36,37 and angiotensin I2
has much lower affinity for both subtypes of mam-
w xmalian receptors 16,36,37 . In our studies with the
catfish AII receptor, AII was approximately 17-fold
more potent than angiotensin III and 27-fold more
potent than angiotensin I.
Xenopus lae˝is express atypical receptors with low
w xaffinity for losartan and PD123177 11–14 . There
are some differences in affinities for AII analogues,
between the X. lae˝is atypical AII receptor and the
catfish receptor. X. lae˝is myocardial receptors have
w xvery high affinity for AI and AII 12 . Nevertheless,
these amphibian AII receptors are functionally cou-
pled to the phosphoinositide turnover signal transduc-
tion pathway that leads to mobilization of intra-
2q w xcellular Ca stores 12,13 , in a fashion similar to
the catfish receptor. Interestingly, the atypical AII
w xreceptors expressed in Pekin duck adrenal 16 have
affinities for AII analogues similar to those of the
catfish receptors.
The atypical AII receptors detected in mouse neu-
w x w xroblastoma 17 and rat intestinal epithelial cells 19
markedly differ from those of catfish liver. The bind-
ing sites in neuroblastoma cells have high affinity for
 .AII 7 nM but very low affinity for angiotensin III
w x17 . The order of potency observed in rat intestinal
cells was very different to that of the present study,
w xi.e., angiotensin I)AII4angiotensin III 19 .
Interestingly, mutational analysis of the AT recep-1
tor has shown that the binding site of non-peptide
antagonist is distinct from the site at which peptides
w xbind to the receptor 38,39 . This has been confirmed,
in a very elegant study, in which the residues re-
quired for losartan binding in the mammalian recep-
tor were exchanged for the corresponding aminoacids
in the Xenopus receptor to generate a mutant am-
phibian receptor that bound losartan with the same
w xaffinity as the rat AT receptor 40 .1
In summary, our data clearly indicate that AII
receptors are present in catfish liver and that they
w 2qxmodulate Ca and phosphoinositide turnover.I
These receptors have pharmacological characteristics
distinct from mammalian AT and AT receptors,1 2
and should be considered among the atypical AII
receptors.
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